📰 Invo Bioscience News
Page 4 - Invo Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Invo Bioscience. Real-time updates on events, politics, business and more.
October 21, 2022
/PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...
October 17, 2022
/PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the worlds only in vivo Intravaginal Culture System...
August 25, 2022
/PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...
August 15, 2022
/PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced...
August 4, 2022
/PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...
June 9, 2022
Invo Bioscience (OTCMKTS:IVOB – Get Rating) and InVivo Therapeutics (NASDAQ:NVIV – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk. Insider and Institutional Ownership 18.6% of InVivo Therapeutics shares […]
June 2, 2022
INVO Bioscience, Inc. (NASDAQ:INVO – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 71,800 shares, an increase of 22.5% from the April 30th total of 58,600 shares. Based on an average trading volume of 38,800 shares, the […]
May 28, 2022
INVO Bioscience (NASDAQ:INVO – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The firm currently has a $1.25 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 16.28% from the stock’s current […]
May 27, 2022
INVO Bioscience (NASDAQ:INVO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. […]
May 26, 2022
INVO Bioscience (NASDAQ:INVO – Get Rating) had its price target lowered by stock analysts at Maxim Group to $3.00 in a report issued on Thursday, Stock Target Advisor reports. Maxim Group’s price objective points to a potential upside of 200.00% from the company’s current price. INVO has been the subject of a number of other […]